ストックスクリーナーアプリを入手
6.21
3.85%
0.23
アフターアワーズ：
6.21
前日終値:
$5.98
開ける：
$6.17
24時間の取引高:
6.70M
Relative Volume:
1.87
時価総額：
$2.01B
収益：
$493.67M
当期純損益:
$-104.69M
株価収益率:
-18.26
EPS:
-0.34
ネットキャッシュフロー:
$-31.51M
1週間 パフォーマンス:
-4.90%
1か月 パフォーマンス:
-4.17%
6か月 パフォーマンス:
-40.80%
1年 パフォーマンス:
-32.72%
1日の値動き範囲:
$6.09
$6.31
1週間の範囲:
$5.82
$6.585
52週間の値動き範囲:
$5.82
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
名前
Amicus Therapeutics Inc
セクター
電話
(609) 662-2000
住所
47 HULFISH STREET, PRINCETON, NJ
FOLD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
6.21 | 2.01B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | 開始されました | Jefferies | Buy |
| 2024-05-30 | 開始されました | Wells Fargo | Overweight |
| 2024-05-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 再開されました | Goldman | Neutral |
| 2022-01-14 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | アップグレード | Stifel | Hold → Buy |
| 2021-09-30 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 再開されました | BTIG Research | Buy |
| 2021-05-27 | 開始されました | Needham | Hold |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 開始されました | Stifel | Hold |
| 2021-02-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-02-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-17 | 開始されました | H.C. Wainwright | Buy |
| 2019-06-05 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 開始されました | Janney | Buy |
| 2019-01-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 開始されました | Citigroup | Neutral |
| 2018-08-17 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
| 2017-09-13 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-08-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-01-24 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 開始されました | BofA/Merrill | Buy |
| 2016-04-14 | 開始されました | Robert W. Baird | Neutral |
| 2016-04-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2015-09-16 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Amicus Therapeutics Inc (FOLD) 最新ニュース
Bayesian Capital Management LP Purchases 54,100 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
Balyasny Asset Management L.P. Has $8 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Algert Global LLC Buys 165,923 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Schonfeld Strategic Advisors LLC Has $1.94 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Marshall Wace LLP Boosts Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference - GlobeNewswire
Oversold Conditions For Amicus Therapeutics (FOLD) - Nasdaq
Dimerix strikes $601M Amicus deal for kidney disease drug DMX-200 - BioWorld MedTech
Pompe Disease Market Expected to Experience Major Growth - openPR.com
Voya Investment Management LLC Sells 743,492 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Aquatic Capital Management LLC - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by PDT Partners LLC - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Tower Research Capital LLC TRC - MarketBeat
Amicus Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Dark Forest Capital Management LP Purchases Shares of 38,148 Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
UBS Raises Price Target for Amicus Therapeutics (FOLD) to $22, M - GuruFocus
UBS Raises Price Target for Amicus Therapeutics (FOLD) to $22, Maintains Buy Rating | FOLD Stock News - GuruFocus
Amicus Therapeutics (FOLD) Target Price Lowered by Goldman Sachs | FOLD Stock News - GuruFocus
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls - TradingView
UBS Boosts Amicus (FOLD) Price Target Despite Revised Pompe Dise - GuruFocus
UBS Boosts Amicus (FOLD) Price Target Despite Revised Pompe Disease Outlook | FOLD Stock News - GuruFocus
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2025 Earnings Call Transcript - Insider Monkey
UBS Adjusts Amicus Therapeutics Price Target to $22 From $21, Maintains Buy Rating - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Dimerix and Amicus to commercialise DMX-200 in US - MSN
Amicus Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$0.07 - GuruFocus
Investor Network: Amicus Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Dimerix and Amicus Therapeutics Announce Exclusive License Agree - GuruFocus
Amicus Therapeutics Turns to Non-GAAP Q1 Earnings, Revenue Rises; Shares Down - marketscreener.com
Earnings call transcript: Amicus Therapeutics reports Q1 2025 loss, stock drops - Investing.com India
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates - Yahoo Finance
Amicus Therapeutics: Q1 Earnings Snapshot - San Antonio Express-News
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates - The Manila Times
Amicus Therapeutics Q1 2025 slides: 15% revenue growth, new kidney disease program - Investing.com
Amicus (FOLD) Shows Strong Revenue Growth Amid Recent Quarter Ch - GuruFocus
BRIEF-Amicus Therapeutics Q1 Revenue USD 125.2 Million Vs. IBES Estimate USD 135.9 Million - TradingView
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Target Price at $16.75 - MarketBeat
Amicus Therapeutics Signs Exclusive License Deal for Dimerix Kidney Disease Therapy - marketscreener.com
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States - The Manila Times
Dimerix Licenses Exclusive U.S. Rights for DMX-200 to Amicus Therapeutics for FSGS Treatment - Nasdaq
Amicus Pays $30M Upfront, Up to $560M Milestones for Breakthrough FSGS Drug Rights - Stock Titan
Amicus Therapeutics Q1 2025 Earnings Preview - MSN
Amicus Therapeutics Earnings Preview - Nasdaq
Amicus Therapeutics Inc (FOLD) 財務データ
収益
当期純利益
現金流量
EPS
4.10%
大文字化:
|
ボリューム (24 時間):